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Abstract
Aims/hypothesis Cardiac disease remains the leading
cause of mortality in type 2 diabetes, yet few strategies
to target cardiac dysfunction have been developed. This
randomised controlled trial aimed to investigate high
intensity intermittent training (HIIT) as a potential therapy
to improve cardiac structure and function in type 2 diabe-
tes. The impact of HIIT on liver fat and metabolic control
was also investigated.
Methods Using an online random allocation sequence,
28 patients with type 2 diabetes (metformin and diet controlled)
were randomised to 12 weeks of HIIT (n=14) or standard care
(n=14). Cardiac structure and function were measured by 3.0 T
MRI and tagging. Liver fat was determined by 1H-magnetic
resonance spectroscopy and glucose control by an OGTT.
MRI analysis was performed by an observer blinded to group
allocation. All study procedures took place in Newcastle upon
Tyne, UK.
Results Five patients did not complete the study and were
therefore excluded from analysis: this left 12 HIIT and 11 con-
trol patients for the intention-to-treat analysis. Compared with
controls, HIIT improved cardiac structure (left ventricular wall
mass 104±17 g to 116±20 g vs 107±25 g to 105±25 g,
p<0.05) and systolic function (stroke volume 76±16 ml to
87±19 ml vs 79±14 ml to 75±15 ml, p<0.01). Early diastolic
filling rates increased (241±84 ml/s to 299±89 ml/s vs
250±44 ml/s to 251±47 ml/s, p<0.05) and peak torsion
decreased (8.1±1.8° to 6.9±1.6° vs 7.1±2.2° to 7.6±1.9°,
p<0.05) in the treatment group. Following HIIT, there was a
39% relative reduction in liver fat (p<0.05) and a reduc-
tion in HbA1c (7.1±1.0% [54.5 mmol/mol] to 6.8±0.9%
[51.3 mmol/mol] vs 7.2±0.5% [54.9 mmol/mol] to 7.4±0.7%
[57.0 mmol/mol], p<0.05). Changes in liver fat correlated with
changes in HbA1c (r=0.70, p<0.000) and 2 h glucose (r=
0.57, p<0.004). No adverse events were recorded.
Conclusions/interpretation This is the first study to dem-
onstrate improvements in cardiac structure and function,
along with the greatest reduction in liver fat, to be record-
ed following an exercise intervention in type 2 diabetes.
HIIT should be considered by clinical care teams as a
therapy to improve cardiometabolic risk in patients with
type 2 diabetes.
Trial registration: www.isrctn.com 78698481
Funding: Medical Research Council.
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V

O2peak Peak oxygen consumption
Introductioṅ
Heart disease is the leading cause of morbidity and mortality
in type 2 diabetes [1], and more than a quarter of all hospital
admissions for heart failure in the West involve a patient with
diabetes [2, 3]. Early changes in left ventricular structure and
function have been identified in adults with type 2 diabetes
prior to any overt cardiac disease. These include pathological
hypertrophy [4], reduced end-diastolic blood volume [5], dia-
stolic and systolic dysfunction [5–7], and alterations in strain
patterns [6, 8], as identified using sensitive magnetic reso-
nance techniques. MRI measurement has been shown to have
greater reproducibility than two-dimensional echocardiogra-
phy in healthy and failing hearts, while avoiding the ionising
radiation exposure associated with computed tomography
methods, permitting ethical longitudinal studies [9]. Despite
clear cardiac dysfunction in type 2 diabetes, therapies to target
these preclinical cardiac changes are sparse.
Treatment algorithms for type 2 diabetes support a physi-
cally active lifestyle at every stage of treatment [10]. Indeed,
aerobic and resistance exercises have known benefits to
cardiovascular function [11], although little is known about
the impacts on cardiac structure and function. More recently,
attention has been given to the intensity of exercise, with high
intensity intermittent training (HIIT) fast becoming a popular
alternative to continuous moderate exercise [12]. HIIT refers
to brief intervals of vigorous activity interspersed with periods
of low activity or rest, and elicits a strong cardiac response
compared with moderate continuous exercise [12, 13]. It
therefore has the potential to improve cardiac structure and
function in type 2 diabetes. However, the cardiac benefits of
HIIT in type 2 diabetes are still to be determined, and the
metabolic effects are also unclear. Only two 12 week HIIT
studies have shown improvements in HbA1c [14, 15], and
the impact of HIIT on ectopic fat (which plays an important
role in glucose homeostasis [16, 17]) has not been investigat-
ed. We therefore aimed to define the effect of HIIT on cardiac
structure and function, regional fat deposition, and glycaemic
control in people with type 2 diabetes. We hypothesised that
HIITwould improve cardiac structure and function, alongside
improving glycaemic control and reducing ectopic fat, in
adults with type 2 diabetes.
Methods
Patients Type 2 diabetic patients (stable control with diet and/or
metformin for at least 6 months) were randomised to a HIIT
(n=14) or a control group (n=14). Participant characteristics
can be seen in Table 1. Participants were excluded if they had
any overt cardiac disease, took part in regular exercise (≥60 min
moderate–vigorous activity per week), were being treated with
β-blocker medication or had any contraindications to exercise
stress testing according to guidelines [18]. The study was
approved by the Newcastle and Northeast Tyneside Local
Research Ethics Committee and all participants provided writ-
ten informed consent. Participants were recruited via advertis-
ing in local newspapers and diabetes community groups
between September 2012 and September 2013. During the
study, two participants left for unrelated medical reasons, one
participant could not commit the time and two failed to comply
with MRI procedures, leaving 12 in the HIIT group and 11 in
the control group (Fig. 1).
Experimental protocol and randomisation Following an
initial screening visit, cardiac structure and function, liver
and visceral fat, body composition, glycaemic control and
blood variables were measured at baseline and after 12 weeks
of HIIT or continued standard care. Glucose control was mea-
sured within 48–72 h of the final exercise session to control
for the acute effect of exercise on glucose uptake. Patients
were randomised into groups using a simple random alloca-
tion sequence (www.randomization.com). Concealed
envelopes with consecutive numbers were locked in a
drawer and withdrawn in numerical order by the main
author (SC).
Screening To determine underlying cardiac disease, a medical
history, physical examination, and resting and exercise 12-lead
Table 1 Participant characteristics
Characteristic Control group HIIT group p value
n (men/women) 8/3 10/2
Age (years) 59±9 61±9 0.70
Time since diagnosis (years) 4±2 5±3
BMI (kg/m2) 32±6 31±5 0.71
Height (cm) 169±9 171±8 0.71
Weight (kg) 90±9 90±15 0.95
HbA1c (%) 7±0.5 7±1 0.87
HbA1c (mmol/mol) 55±6 54±11 0.88
Fasting glucose (mmol/l) 7.0±1.0 6.8±1.6 0.69
2 h glucose (mmol/l) 11.7±3.1 12.5±3.1 0.57
Liver fat (%) 7.1±6.8 6.9±6.9 0.94
V

O2peak (ml kg
−1 min−1) 20.3±6.1 21.8±5.4 0.54
Medications
Metformin 7 7
Statins 6 7
BP 5 3
V

O2peak is normalised to body mass
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electrocardiography (Custo med, Ottobrunn, Germany) were
performed. During the exercise test, gas exchange was mea-
sured to determine peak oxygen consumption (V

O2peak )
normalised to body mass. V

O2peak was determined as the point
at which participants reached volitional exhaustion, participants
could no longer maintain a cycling rate of 60 rev/min, or con-
tinuing exercise was contraindicated [18]. The test was per-
formed using an electronically braked semirecumbent cycle
ergometer (Corival Lode, Groningen, The Netherlands) and
resistance was increased by 1 Wevery 6 s. Before the exercise
test, patients completed a 20 min resting period in which they
lay supine while beat-to-beat BP was measured by the vascular
unloading technique [19].
Cardiac MRI All examinations were performed using the
3.0 T Philips Achieva MRI scanner with a six channel cardiac
array (Philips Medical Systems, Best, The Netherlands).
During breath holding, a stack of balanced steady-state free
precession images were obtained in the short axis view, cov-
ering the entire left ventricle (field of view [FOV]=350 mm,
repetition time [TR] / echo time [TE]=3.7/1.9 ms, turbo factor
17, flip angle 40°, slice thickness 8 mm, 0 mm gap, 14 slices,
25 phases, resolution 1.84×1.37 mm with zero filling to
1.37×1.37 mm and temporal duration approximately 40 ms
per phase, dependent on heart rate). Using a Viewforum
workstation (Philips Medical Systems), the short axis slices
at end-diastole and end-systole were used (Fig. 2a) to manu-
ally trace endocardial and epicardial borders, with papillary
muscles excluded from volume calculations but included in
calculations of left ventricular mass. The apical slice was de-
fined as the last slice showing inter-cavity blood pools, and the
basal slice as the last slice in which at least 50% of the blood
volume was surrounded by myocardium. The analysis was
performed by a single observer blinded to group allocation.
Details of the algorithm for contour selection and calculation
of left ventricular mass, systolic and diastolic variables have
been previously published [20]. The eccentricity ratio is a
measure of concentric remodelling, and was calculated by
dividing left ventricular mass by end-diastolic blood volume.
Longitudinal shortening was determined from cineMRI in the
four-chamber view by determining the perpendicular distance
from the plane of the mitral valve to the apex in systole and
diastole.
Cardiac tagging Tagged short axis images were acquired.
Cardiac tagging works by applying radiofrequency pulses to
cancel the MR signal from the myocardium in diastole in a
rectangular grid pattern and tracking the deformation of these
tags through the rest of the cardiac cycle (Fig. 2a). A turbo-field
echo sequence with acceleration factor 9 was used (TR=4.9,
Assessed for eligibility
(n=256) 
Excluded (n=228)
- Not meeting inclusion criteria (n=201) 
- Declined to participate (n=16)
- Other reasons (did not re-contact,
      n=11) 
Analysed (n=11)
- Excluded from analysis (n=0)
Discontinued intervention (could not commit 
time, n=1) 
Allocated to control (n=14)
- Received allocated intervention (n=12)
- Did not receive allocated intervention (did
not want to go through MRI again, n=2) 
Discontinued intervention (unrelated medical 
problems, n=2) 
Allocated to exercise (n=14)
- Received allocated intervention (n=14)
- Did not receive allocated intervention (n=0)
Analysed (n=12)
- Excluded from analysis (n=0)
Analysis
Allocation
Follow-up
Randomised (n=28)
Enrolment
Fig. 1 Consort flow diagram
showing patient numbers at each
stage of the trial
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TE=3.1, flip angle=10°, number of excitations=1, SENSE
factor 2, FOV 350×350 mm, voxel size 1.37×1.37 mm with
no zero filling and an orthogonal complementary spatial mod-
ulation of magnetistion grid with tag spacing of 7 mm). Short
axis slices of 10 mm thickness were prescribed. The Cardiac
Image Modelling package (University of Auckland, New
Zealand) was used to analyse the tagging data by aligning a
mesh on the tags between the endo- and epicardial contours.
Details of the calculation of strain and torsion variables have
been previously published [21].
Cardiac spectroscopy Cardiac high-energy phosphate
metabolism was assessed using 31P-magnetic resonance spec-
troscopy (see Fig. 2b for an example cardiac spectrum). Cardiac
acquisition was vectorcardiogram-gated with the participant in
a prone position during free breathing, with a 10 cm diameter
31P surface coil used for transmission/reception (PulseTeq,
Chobham, UK) and the scanner body coil used for localising
images. A cardiac gated one-dimensional chemical shift imag-
ing sequence was used, and to eliminate contamination from
liver, a 7 cm slice was selected in the foot–head direction using
a selective pulse (of the ‘spredrex’ type, as outlined in [22]).
The flip angle subtended at the myocardium was fixed to
achieve 50° excitation at the target depth and measured using
a variable flip angle sequence on a gadolinium-doped
20 mmol/l phenyl phosphonic acid phantom at the centre of
the coil. Sixteen coronal phase-encoding steps yielded spectra
from 10 mm slices (TR=heart rate, 192 averages, acquisition
time approximately 20 min), using a trigger delay of 400 ms.
A cosine apodisation filter was applied. The first spectrum
containing signal beyond the chest wall and solely from car-
diac tissue was selected. The spectrum was analysed using an
AMARES time domain fit algorithm in jMRUI [23] and the
ATP peak area was corrected for blood contamination [24].
Liver and visceral fat MRI Liver fat was assessed by
1H-magnetic resonance spectroscopy (TR/TR=3,000 ms/35,
50, 75, 100, 125 or 150 ms, 3×3×3×3 cm voxel, SENSE
torso array, one signal average and an expiration breath hold
of 17 s). The water and CH2 resonances were analysed using
the AMARES algorithm in jMRUI [23]. The T2 relaxation
times of the water and CH2 resonances for each participant
were calculated from the data by monoexponential fitting of
signal intensity vs the six echo times, the signals at 35mswere
then corrected for T2 decay and the fat fraction was calculated
as a percentage of the total signal from that volume [25].
Visceral fat was estimated at the L4–L5 junction [26]
using a three-point Dixon sequence (TR=50 ms, TE=3.45,
4.60 or 5.75 ms, number of averages=1, flip angle=5°,
voxel size 2.5×2.5 mm, slice thickness 10 mm, zero filled
to 1.4×1.4mm, andmedian FOV 440mm [range 400–480mm
to suit participant size], with 70% phase FOV) [27]. Binary
gating and a watershed algorithm was used to divide the binary
image into distinct areas (Fig. 3); this allowed easy separation
and quantification of the subcutaneous and visceral fat areas
using ImageJ [28]. Liver and visceral fat analyses were per-
formed by a single observer blinded to group allocation.
Glycaemic control, blood variables and body composition
After an 8 h minimum overnight fast, a 75 g OGTT was
performed in which samples were drawn every 15 min and
analysed for whole blood glucose (YSI 2300 Stat Plus-D,
Yellow Springs Instruments, Yellow Springs, OH, USA) and
plasma insulin (Mercodia Iso-Insulin ELISA, no. 10-1128-01,
Mercodia, Uppsala, Sweden). Insulin resistance and beta cell
function were predicted using the HOMA2 [29], and the area
under the glucose curve (AUGC) was calculated using the
trapezoidal rule [30]. Fasting plasma samples were analysed
in an accredited clinical pathology laboratory (Department of
Clinical Biochemistry, Newcastle upon Tyne Hospital NHS
10 5 0 -15-5
Chemical shift (ppm)
-10
PCr
γ-ATP
α-ATP
β-ATP
PDE
2,3-DPG
b
a
I II
III IV
Fig. 2 Cardiac MRI techniques. These include (a) Cardiac cine imaging
(I, II) and cardiac tagging (III, IV) at diastole (I, III) and systole (II, IV),
showing how a rectangular grid of nulled signal applied at diastole remains
with the tissue through the cardiac cycle, allowing calculation of strain and
torsion. (b) Phosphorus spectroscopy. Spectrum presented before correc-
tion for saturation due to blood content, flip angle at the cardiac tissue and
heart rate. DPG, diphosphoglycerate; PDE, phosphodiesters
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Foundation Trust) for alanine phosphatase (ALP), alanine
transaminase (ALT), aspartate aminotransferase (AST), total
cholesterol, triacylglycerols and HbA1c. Total cholesterol, tri-
acylglycerols, ALP, AST and ALT were measured using a
Roche P800 Modular Analyzer (Basel, Switzerland) and
HbA1c was measured using a TOSOH HLC-723G8 (Minato,
Tokyo, Japan). Body composition was measured using air
displacement plethysmography (BodPod, Life Measurement,
CA, USA).
Intervention The HIIT group performed 36-cycle ergometry
sessions over 12 weeks (3 sessions per week on non-
consecutive days) at a local gym. Patients were required to
perform at least 32 sessions (89% of total sessions) for inclu-
sion in the analysis. Intensity was based on the 6–20 point
Borg Rating of Perceived Exertion (RPE) [31]. Each session
included a 5 min warm up in which participants would prog-
ress from RPE 9 to 13 (‘very light’ to ‘somewhat hard’),
followed by five intervals, each with a pedal cadence of >80
rev/min, reaching a RPE 16–17 (‘very hard’). The final inter-
val was then followed by a 3 min recovery cycle. Intervals
lasted 2 min in week 1 and progressed by 10 s increments each
week such that week 12 consisted of 3 min 50 s intervals.
Three min recovery periods interspersed each interval, which
consisted of 90 s passive recovery, 60 s of band-resisted upper
body exercise and 30 s to prepare for the subsequent interval.
The arm resistance bands (Bodymax Fitness, Clydebank, UK)
were used as light recovery and involved one exercise per
recovery period in the following order: face pull, horizontal
push, horizontal pull and 30° push. The initial session was
supervised; thereafter, participants were guided through each
session by voice-recorded instructions using an iPod shuffle
(Apple, CA, USA). An exercise diary was completed to mon-
itor exercise adherence.
Apart from HIIT sessions, all study participants were
instructed to continue their normal routine and care for
12 weeks and not to change medication, habitual physical
activity, diet or body weight. Weekly phone calls were made
to assess adherence, and habitual physical activity was
assessed over 7 days pre- and post-intervention using a vali-
dated multisensory armband (Sensewear; Bodymedia,
Pittsburgh, PA, USA) [32].
Statistical analysis Statistical power was based on the change
in HbA1c.We selected a sample size of 12 to provide a statistical
power of 80% to detect a difference of 0.6% in HbA1c [33]. A
sample size of 14 was used to allow for two dropouts per group.
A per-protocol analysis was adopted because the intention of
this study was to assess efficacy and mechanisms of change,
not effectiveness. All analyses were performed using IBM
SPSS Statistics software (version 19, NY, USA) and data are
presented as means±SD unless otherwise stated. Continuous
data were tested for normality using the Shapiro–Wilk test.
Comparisons of key baseline variables were made using inde-
pendent sample t tests. Between-group comparisons were made
using ANCOVA with the baseline value as the covariate.
Within-group changes were assessed by paired-sample t tests
or the non-parametric alternative (Wilcoxon signed-rank test)
for non-normally distributed data. Adjustment for multiple com-
parisons was not made because of co-linearity between vari-
ables, hypothesis-driven comparisons and the increased risk of
type II error following adjustment [34]. Pearson’s correlation or
the non-parametric alternative (Spearman’s rank correlation)
was used to calculate r values among body composition, meta-
bolic and cardiac variables. P values <0.05 were considered
statistically significant.
Results
The groups were matched well for all baseline characteristics
(Table 1). Glycaemic control was similar between groups and
liver fat was above the clinically defined threshold for non-
alcoholic fatty liver disease (>5%) in both groups. Adherence
a
b
c
Fig. 3 Quantifying visceral fat. (a) The three-point Dixon fat fraction
map acquired at the L4–L5 junction. (b) Binary thresholding of structures
containing more than 50% fat (visceral and subcutaneous fat) from those
with less. Total area is evaluated. (c) Application of thresholding algo-
rithm divides segmented image into chunks and separates visceral and
subcutaneous fat around the boundary of the chest wall. Selection of
subcutaneous fat and any external signals allows measurement of this
area and subtraction from the total to yield visceral fat area
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to intervention was good, with HIIT patients completing an
average of 36±0.9 sessions, and Sensewear armband activity
revealed no within-group change in habitual physical activity
(daily energy expenditure: HIIT 2,701±299 to 2,537±386,
p=0.129 vs control 2,548±366 to 2,455±166, p=0.459
(calories)).
Cardiac structure, function and energetics HIIT induced
structural cardiac changes, with a 12% relative increase in left
ventricular wall mass (p<0.05) and increased end-diastolic
blood volume (p<0.01; Fig. 4a). The exercise group also
demonstrated improvements in systolic function, indicated
by raised stroke volume (p<0.01) and left ventricular ejection
fraction (p<0.05). The early diastolic filling rate increased by
24% (Fig. 4b), and within-group comparison revealed a sig-
nificant increase in early filling percentage after HIIT (57±9%
to 60±9%, p<0.05; Table 2). There was a 15% relative
decrease in peak torsion after exercise (8.1±1.8° to 6.9±1.6°
vs 7.1±2.2° to 7.6±1.9°; p<0.05; Fig. 4c); myocardial strain
remained constant. The phosphocreatine (PCr)/ATP ratio did
not change following HIIT (p=0.115; Table 2).
Body composition Within-group comparisons revealed no
change in body weight after exercise. However, the 1%
increase and decrease in control and HIIT, respectively, was
a significant between-group interaction (p<0.05; Table 3).
There was no effect of HIIT on whole body fat mass but
within-group comparison revealed a reduction in visceral
adipose tissue (201±80 cm2 to 181±72 cm2, p<0.05;
Table 3). The change in whole body fat mass (in kg) was
associated with changes in 2 h glucose (r=0.46, p=0.027)
and HbA1c (r=0.60, p=0.003).
Liver fat and enzymesHIITelicited a 39% relative reduction
in liver fat (6.9±6.9% to 4.2±3.6%, p<0.05) so that four
patients in the exercise group moved from having clinically
significant liver fat to within ‘normal’ limits (<5%, Table 3).
There was a significant between-group interaction for HIIT
and liver fat (p<0.05; Table 3), accompanied by within-
group changes in ALT and AST (p<0.5; Table 3), both
markers of liver damage. Change in liver fat correlated with
change in fasting glucose (r=0.45, p=0.030), 2 h glucose
(r=0.57, p=0.004) and HbA1c (r=0.70, p=0.000).
Glycaemic control HIIT had no impact on fasting glucose
(6.8±1.6 mmol/l to 6.8±1.6 mmol/l, p=0.866) or fasting
insulin (65.5±39.5 pmol/l to 65.5±32.8 pmol/l, p=0.875);
however, between-group comparisons revealed improvements
in HbA1c, 2 h glucose and AUGC (p<0.05; Table 3). There
was no improvement in insulin sensitivity (HOMA2 of insulin
resistance [HOMA2-IR] and HOMA2 of insulin sensitivity
[HOMA2-%S]) or beta cell function (HOMA2 of beta cell
function [HOMA2-β]).
Discussion
This is the first study to examine the effects of HIITon cardiac
structure and function, regional fat deposition, and glycaemic
control in people with type 2 diabetes. The main findings were
that a 12 week HIIT programme increased left ventricular wall
mass and end-diastolic blood volume, improved systolic and
diastolic function, reduced peak torsion, and decreased liver
fat. Therefore, HIITwas an effective strategy to reverse cardi-
ac dysfunction and reduce liver fat in this patient group and
was accompanied by modest improvements in glycaemic
control.
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Fig. 4 Effect of HIIT vs control on (a) left ventricular mass, (b) diastolic
filling rate and (c) peak torsion. White bars, control; black bars, HIIT.
Values are means±SEM. *Significant difference baseline vs post-treat-
ment (p<0.05). †Significant difference between-group interaction
(p<0.05)
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Cardiac changes Left ventricular wall mass and end-
diastolic blood volume increased after 12 weeks of HIIT.
This ‘physiological hypertrophy’ is a known effect of exercise
but should not be confused with ‘pathological hypertrophy’,
as seen in those with type 2 diabetes [4, 35]. An increase in
cardiomyocyte size and protein synthesis is observed during
physiological and pathological hypertrophy in response to
either growth or stress signals, respectively [35]. These condi-
tions differ in that only pathological hypertrophy is
characterised by collagen accumulation and increased wall
thickness, which compromises end-diastolic blood volume
and is an independent predictor of cardiovascular death [36].
This is the first study using MRI to show that HIIT can stimu-
late positive cardiac remodelling.
The increase in stroke volume and ejection fraction is
important because those with type 2 diabetes have reduced
cardiac contractile capabilities [4]. Cardiomyocyte responses
to high intensity exercise training in animal models have dem-
onstrated improvements in the maximal extent of shortening,
contraction and relaxation rates, with twice the improvement
seen after training at 85–90% compared with training at
65–70% V

O2peak [37]. The increased myofilament sensitivity
Table 2 Effect of HIIT on cardiac structure, function and metabolism
Parameter Control HIIT Adjusted between-
group p valueb
Pre Post Within-
group p
valuea
Pre Post Within-
group p
valuea
Cardiac structure
Left ventricular wall mass (g) 107±25 105±25 0.54 104±17 116±20 0.02* 0.03†
Wall thickness systole (mm) 5.5±1.1 6.2±1.0 0.01** 6.2±1.5 6.8±1.1 0.07 0.54
Wall thickness diastole (mm) 9.1±2.5 10.1±2.5 0.02* 10.7±3.1 11.5±1.8 0.32 0.43
Eccentricity ratio (g/ml) 0.85±0.24 0.87±0.18 0.66 0.94±0.28 0.96±0.24 0.70 0.66
End-diastolic volume (ml) 129±28 122±28 0.08 118±30 126±30 0.01** 0.00††
End-systolic volume (ml) 50±22 47±22 0.33 42±17 39±13 0.25 0.76
Systolic function
Systolic BP (mmHg) 126±3 124±5 0.62 123±4 122±4 0.66 0.99
Diastolic BP (mmHg) 84±2 80±2 0.07 81±2 80±2 0.81 0.41
Heart rate (bpm) 63±7 69±13 0.21 67±12 66±16 0.69 0.27
Stroke volume (ml) 79±14 75±15 0.16 76±16 87±19 0.00** 0.00††
Cardiac output (l/min) 5.0±1.0 5.2±1.0 0.54 5.0±1.00 5.5±1.0 0.07 0.31
Ejection fraction (%) 64±11 63±10 0.62 65±8 70±6 0.02* 0.03†
Longitudinal shortening (%) 13.1±2.2 12.7±2.6 0.62 12.2±3.0 13.4±1.8 0.28 0.39
Diastolic function
Early filling percentage (%) 58±11 59±8 0.88 57±9 60±9 0.04* 0.45
Early diastolic filling rate (ml/s) 250±44 251±47 0.68 241±84 299±89 0.01** 0.02†
Late diastolic filling rate (ml/s) 310±143 285±60 0.68 278±67 289±64 0.53 0.56
Strain and torsion
Peak endocardial circumferential strain (%) 23.1±4.1 23.4±4.3 0.82 25.2±4.6 24.5±5.1 0.61 0.82
Peak whole wall circumferential strain (%) 16.5±3.1 16.0±3.3 0.46 16.5±3.1 16.4±4.0 0.94 0.73
Peak torsion (°) 7.1±2.2 7.6±1.9 0.19 8.1±1.8 6.9±1.6 0.04* 0.04†
Metabolism
PCr/ATP ratio 1.76±0.51 1.72±0.36 0.80 1.74±0.39 2.00±0.36 0.19 0.12
Data are mean±SD
a Paired t test
b Adjusted for baseline value for ANCOVA
*Significant difference baseline vs post-treatment (p<0.05)
**Significant difference baseline vs post-treatment (p<0.01)
† Significant difference between-group interaction (p<0.05)
†† Significant difference between-group interaction (p<0.01)
bpm, beats per minute; pre, pre-treatment; post, post-treatment
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to calcium and the faster rise and diastolic decay of the calci-
um transient underpins these changes [37].
The early filling rate increased by 24%, suggesting that the
myocardium is more compliant and quicker to relax following
HIIT. Diastolic dysfunction is the most widely reported mal-
function of the diabetic heart and an independent predictor of
mortality [5, 7, 38], thus emphasising the clinical relevance of
these findings. One study using echocardiography demon-
strated diastolic improvements following 12 weeks of HIIT
[14] and a longer term intervention using moderate exercise
demonstrated improvements only when exercise was per-
formed in the vigorous zone [39].
The decrease in torsion after HIIT provides, for the first
time, evidence that exercise can be used to reverse the raised
cardiac torsion observed in type 2 diabetes [8]. Cardiac torsion
is a normal feature of contraction in a healthy heart and reflects
the dominance of epicardial fibres over endocardial fibres
[40]. Raised torsion in type 2 diabetes is a consequence of
impaired contraction of endocardial fibres, which are less able
to counteract this twisting motion [40]. These results indicate
that endocardial damage and potential perfusion deficits at the
endocardium can be improved with HIIT. No change was
observed in peak endocardial and peak whole wall circumfer-
ential strain because the relative contribution of fibres across
the myocardial wall remained constant, as reflected by the
maintained eccentricity ratio.
HIIT stimulated improvements in cardiac structure and
function independent of changes in cardiac metabolism. It
Table 3 The effect of HIIT on body composition, blood variables and metabolic control
Parameter Control HIIT Adjusted between-
group p valueb
Pre Post Within-
group p
valuea
Pre Post Within-
group p
valuea
Body composition
Weight (kg) 90±9 91±10 0.06 90±15 89±15 0.09 0.02†
Fat mass (kg) 35.6±10.9 36.0±11.3 0.36 31.9±9.3 30.8±10.2 0.09 0.08
Fat free mass (kg) 54.3±5.9 54.7±5.7 0.28 57.7±9.0 58.2±8.9 0.34 0.72
Visceral adipose tissue (cm2) 159±58 156±49 0.21 201±80 181±72 0.04* 0.08
Liver fat (%) 7.1±6.8 7.7±6.9 0.12 6.9±6.9 4.2±3.6 0.06 0.01††
Blood variables
ALT (U/l) 34±16 33±14 0.82 36±11 30±10 0.02* 0.14
AST (U/l) 27.6±10.4 26.5±8.8 0.63 27±7 24±6 0.02* 0.25
ALP (U/l) 59.2±16.8 61.2±17.5 0.09 66±17 63±16 0.10 0.03†
Total cholesterol (mmol/l) 4.5±0.9 4.6±0.9 0.62 4.0±1.0 4.5±1.1 0.15 0.77
Triacylglycerol (mmol/l) 1.1±0.4 1.2±0.4 0.12 1.1±0.3 1.2±0.4 0.28 0.87
Metabolic control
HbA1c (%) 7.2±0.5 7.4±0.7 0.07 7.1±1.0 6.8±0.9 0.10 0.02
†
HbA1c (mmol/mol) 54.9±5.9 57.0±7.5 0.06 54.5±10.6 51.3±10.2 0.09
Fasting glucose (mmol/l) 7.0±1.0 7.6±1.4 0.03* 6.8±1.6 6.8±1.6 0.87 0.15
Fasting insulin (pmol/l) 81.5±46.4 88±39.5 0.42 65.5±39.5 65.5±32.8 0.88 0.22
2 h glucose (mmol/l) 11.7±3.1 12.9±2.7 0.01** 12.5±3.1 11.7±3.1 0.22 0.02†
2 h AUGC 1,366±66 1,544±86 0.01** 1,395±81 1,399±87 0.94 0.02†
HOMA-IR 1.6±0.9 1.8±0.8 0.40 1.3±0.8 1.4±0.6 0.94 0.19
HOMA2-β 67.8±31.4 67.0±37.3 0.79 68.9±48.6 70.9±49.0 1.00 0.76
HOMA2-S 76.1±33.0 67.3±29.5 0.25 101.7±48.1 98.2±53.8 0.88 0.39
Data are mean±SD
a Paired t test
b Adjusted for baseline value for ANCOVA
*Significant difference baseline vs post-treatment (p<0.05)
**Significant difference baseline vs post-treatment (p<0.01)
† Significant difference between-group interaction (p<0.05)
†† Significant difference between-group interaction (p<0.01)
Pre, pre-treatment; post, post-treatment
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was previously suggested that defects in cardiac metabolism
underlie cardiac abnormalities seen in type 2 diabetes [7]; how-
ever, the decrease in PCr/ATP ratio in type 2 diabetes most
likely reflects changes in substrate supply to the heart rather
than an underlying metabolic defect in the myocardium [6].
Metabolic changes These data reveal for the first time that
HIITcan reduce liver and visceral fat in type 2 diabetes, which
is clinically important because both fat depots play a key path-
ogenic role in this chronic disease [16, 17]. To our knowledge,
this is the greatest reduction in liver fat to be reported follow-
ing exercise in type 2 diabetes.
Despite this, fasting blood glucose did not change and, in
line with data in healthy adults and obese women [41, 42], the
results demonstrated no impact of HIITon central insulin sen-
sitivity in adults with type 2 diabetes. These results differ from
those obtained after the very low energy diet (2,512 kJ
[600 kcal]), which led to a 30% relative reduction in liver fat
and normalisation of fasting blood glucose after just 7 days
[43]. In the present study, however, there was large inter-
individual variation in liver fat changes after HIIT, which
may explain the absence of change in fasting blood glucose
within this small sample. Indeed, those who lost the greatest
liver fat had the largest reductions in fasting glucose, as
reflected in the significant correlation.
It has been reported that HIIT acutely improves periph-
eral insulin sensitivity when measured within 72 h of the
last exercise bout, attributable to rapid glycogen break-
down and subsequent re-synthesis [41]. The two studies
which have measured postprandial response to HIIT in
type 2 diabetes used continuous blood glucose measure-
ments under standard dietary conditions [44, 45]. Dietary
intake was not standardised in the present study, which
may explain the lack of within-group improvement in 2 h
glucose or HOMA-IR.
Within-group analysis also revealed no significant impact
of HIITon HbA1c. The significant between-group interactions
most likely reflect a worsening of glycaemic control in the
control group. HbA1c was reduced by around 0.3% following
HIIT, which is less than the reported mean effect (0.6% reduc-
tion) of exercise interventions [33]. That being said, the
greatest improvements in 2 h glucose and HbA1c occurred in
those who lost the largest amount of whole body fat mass and
liver fat. As for fasting blood glucose, we speculate that 2 h
glucose and HbA1c within-group changes failed to reach
significance because of the variation in liver fat reductions
following HIIT.
This study questions the impact of HIIT on glycaemic con-
trol in adults with type 2 diabetes, but also confirms the
importance of ectopic fat. Patients were required to maintain
their weight during the HIIT programme, which may have
compromised any improvements in glucose control.
Interventions to target weight loss and ectopic fat may bemost
beneficial for glycaemic improvements. Despite this, these
data highlight the positive impact of exercise on cardiac
health, which may be improved further when accompanied
by weight loss.
This study is not without limitation. The physiological
mechanisms underlying the cardiac adaptations could not
be elucidated with the MRI techniques used. Although
magnetic resonance methods for quantifying ATP flux in
the human heart by cardiac spectroscopy have been dem-
onstrated in heart failure [46], they remain time-
consuming and prone to variability. The PCr/ATP ratio
can be measured in a reasonable period of time and has
been demonstrated to be impaired in type 2 diabetes [47].
Using the RPE as a guide for exercise intensity (rather
than an objective measure) may have limited the accuracy
of the training intensity; however the RPE has been found
to be an accurate predictor of exercise intensity in diabe-
tes [48]. Finally, dietary monitoring was not adopted
throughout the intervention.
In summary, this study demonstrates for the first time
improvements in cardiac structure and function in patients
with type 2 diabetes following a HIIT programme. These
changes were accompanied by modest improvements in
glycaemic control. HIIT elicited the greatest reduction
in liver fat to be recorded following an exercise interven-
tion in type 2 diabetes, demonstrating that this type of
exercise is effective at targeting fat depots which play a
role in the aetiology of this chronic condition. Although
the direct benefits of HIIT to glycaemic control remain
uncertain, HIIT is a potential therapy to moderate cardiac
risk and reduce liver fat in type 2 diabetes and should be
considered by clinicians alongside other regimens to improve
glycaemic control.
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